Genmab A/S (GMAB) Stock Price, News & Analysis

Company Overview

Genmab A/S is a global biotechnology company focused on the creation and development of innovative antibody therapeutics for the treatment of cancer and other serious diseases. Headquartered in Copenhagen, Denmark, the firm leverages proprietary antibody technologies to generate novel drug candidates and advance them through clinical development. Since its inception in 1999, Genmab has established a strong reputation for pioneering bispecific and antibody-drug conjugate platforms that aim to improve patient outcomes by targeting disease pathways with high precision.

The company’s research and development efforts are concentrated on immuno-oncology, using its DUOBODY® bispecific antibody platform to engage two targets simultaneously and enhance immune response against tumor cells. Genmab also applies its GENmab’s HexaBody® and DuoHexaBody® technologies to amplify the immune system’s ability to destroy cancer cells, as well as its ADCC-Enhancer™ technology to increase the potency of monoclonal antibodies. These platforms support a diverse pipeline of clinical-stage candidates in various hematologic and solid tumor indications, often in collaboration with strategic partners.

Genmab has achieved commercial success through collaborations that bring its antibody innovations to market. The company co-developed and licenses several landmark therapies, including the anti-CD38 antibody daratumumab (marketed as DARZALEX®) for multiple myeloma, and the anti-PD-1 antibody combination epcoritamab (developed with AbbVie) for B-cell malignancies. In addition to oncology, Genmab is exploring opportunities in rare and autoimmune diseases, leveraging its expertise in antibody engineering to expand into new therapeutic areas.

Operating globally, Genmab maintains research and development facilities in Denmark and the United States, with commercial and clinical capabilities supported by partnerships in Europe, North America, and Asia. The company’s leadership team is led by CEO Jan van de Winkel, Ph.D., who has guided Genmab through a period of rapid growth and innovation. Under his direction, the board and executive management continue to prioritize cutting-edge science, regulatory excellence, and strategic collaborations to drive long-term value and deliver transformative medicines to patients worldwide.

AI Generated. May Contain Errors.

Key Stats

• Today's Range: $20.46 to $21.08
• 50-Day Range: $19.08 to $23.09
• 52-Week Range: $17.24 to $28.56
• Volume: 668,910 shs
• Average Volume: 1.22 million shs
• Market Capitalization: $13.39 billion
• P/E Ratio: 11.86
• Dividend Yield: N/A
• Price Target: $37.60
• Consensus Rating: Moderate Buy

Genmab A/S Stock Analysis - MarketRank™

Genmab A/S scored higher than 77% of companies evaluated by MarketBeat, and ranked 237th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Genmab A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 7 buy ratings, 3 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Genmab A/S has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 22.76%

Earnings Growth

Earnings for Genmab A/S are expected to grow by 22.76% in the coming year, from $1.45 to $1.78 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Genmab A/S is 11.92, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.83.

Price to Earnings Ratio vs. Sector

The P/E ratio of Genmab A/S is 11.92, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.51.

Price to Earnings Growth Ratio

Genmab A/S has a PEG Ratio of 6.76. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Genmab A/S has a P/B Ratio of 2.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.36% of the float of Genmab A/S has been sold short.

Short Interest Ratio / Days to Cover

Genmab A/S has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Genmab A/S has recently decreased by 8.23%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genmab A/S does not currently pay a dividend.

Dividend Growth

Genmab A/S does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.36% of the float of Genmab A/S has been sold short.

Short Interest Ratio / Days to Cover

Genmab A/S has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Genmab A/S has recently decreased by 8.23%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.88

News Sentiment

Genmab A/S has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Genmab A/S this week, compared to 7 articles on an average week.

Search Interest

Only 4 people have searched for GMAB on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

2 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genmab A/S insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.54% of the stock of Genmab A/S is held by insiders.

Percentage Held by Institutions

Only 7.07% of the stock of Genmab A/S is held by institutions.

GMAB Stock Analysis - Frequently Asked Questions

How have GMAB shares performed this year?

Genmab A/S's stock was trading at $20.87 on January 1st, 2025. Since then, GMAB stock has increased by 0.6% and is now trading at $20.9850.
View the best growth stocks for 2025 here.

How were Genmab A/S's earnings last quarter?

Genmab A/S Sponsored ADR (NASDAQ:GMAB) announced its earnings results on Thursday, May, 8th. The company reported $0.31 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.08. The company earned $715 million during the quarter, compared to analysts' expectations of $5.17 billion. Genmab A/S had a net margin of 35.11% and a trailing twelve-month return on equity of 18.08%.
Read the conference call transcript.

When did Genmab A/S IPO?

Genmab A/S (GMAB) raised $503 million in an IPO on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.

How do I buy shares of Genmab A/S?

Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Genmab A/S own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Genmab A/S investors own include NVIDIA (NVDA), Medtronic (MDT), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Meta Platforms (META), Tesla (TSLA) and Datadog (DDOG).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/01/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GMAB
• CIK: 1434265
• Web: www.genmab.com
• Phone: (457) 020-2728
• Fax: N/A
• Employees: 1,660
• Year Founded: 1999

Price Target and Rating

• Average Stock Price Target: $37.60
• High Stock Price Target: $48.00
• Low Stock Price Target: $27.00
• Potential Upside/Downside: +79.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 12 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $1.76
• Trailing P/E Ratio: 11.92
• Forward P/E Ratio: 14.47
• P/E Growth: 6.76
• Net Income: $1.14 billion
• Net Margins: 35.11%
• Pretax Margin: 40.96%
• Return on Equity: 18.08%
• Return on Assets: 14.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.34
• Quick Ratio: 5.32

Sales & Book Value

• Annual Sales: $3.12 billion
• Price / Sales: 4.31
• Cash Flow: $1.55 per share
• Price / Cash Flow: 13.52
• Book Value: $8.04 per share
• Price / Book: 2.61

Miscellaneous

• Outstanding Shares: 641,220,000
• Free Float: 631,346,000
• Market Cap: $13.46 billion
• Optionable: Optionable
• Beta: 0.96